Financials data is unavailable for this security.
View more
Year on year Chunghwa Chemical Synthesis & Biotech Co Ltd 's revenues fell -35.42% from 2.09bn to 1.35bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 264.91m to 53.03m, a -79.98% decrease.
| Gross margin | 15.54% |
|---|---|
| Net profit margin | -10.53% |
| Operating margin | -18.74% |
| Return on assets | -2.21% |
|---|---|
| Return on equity | -3.14% |
| Return on investment | -2.45% |
More ▼
Cash flow in TWDView more
In 2024, cash reserves at Chunghwa Chemical Synthesis & Biotech Co Ltd fell by 47.29m. However, the company earned 467.65m from its operations for a Cash Flow Margin of 34.71%. In addition the company used 100.10m on investing activities and also paid 415.72m in financing cash flows.
| Cash flow per share | 1.57 |
|---|---|
| Price/Cash flow per share | 23.62 |
| Book value per share | 41.78 |
|---|---|
| Tangible book value per share | 41.75 |
More ▼
Balance sheet in TWDView more
| Current ratio | 3.34 |
|---|---|
| Quick ratio | 1.10 |
| Total debt/total equity | 0.2508 |
|---|---|
| Total debt/total capital | 0.2005 |
More ▼
Growth rates in TWD
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -76.05% and -72.23%, respectively. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked below the industry average relative to its peers.
| Div yield(5 year avg) | 1.80% |
|---|---|
| Div growth rate (5 year) | -24.86% |
| Payout ratio (TTM) | -- |
| EPS growth(5 years) | -8.83 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -247.79 |
More ▼
